Due to the reduction in FGFR activity and the increase in side effects, new-generation FGFR inhibitors have made new progress, mainly including erdafitinib for the treatment of BC containing FGFR2-3 mutations (100); infigratinib to evaluate whether it can be used as adjuvant therapy after surgery (101). Here, FGFR2 is linked to breast cancer.